

FORWARD thinning/thickening manuscript_re-submission_December 2019

Supplementary Table S2 Change from baseline in cartilage thickness (μm) by ordered values at 24 months (mITT Analysis Set)

| Ordered Value | Placebo | Sprifermin 100 μg q6mo |
|----------------------|-------------------------|---|
| Mean (95% CI) | (N=96) | (N=101) |
| OV1 | -199.5 (-242.2, -156.8) | -139.7 (-166.8, -112.5) |
| OV2 | -130.7 (-160.4, -101.1) | -83.0 (-102.0, -64.0) |
| OV3 | -104.7 (-133.3, -76.2) | -50.8 (-65.1, -36.5) |
| OV4 | -80.3 (-106.1, -54.5) | -31.3 (-43.7, -19.0) |
| OV5 | -65.1 (-88.3, -41.9) | -18.0 (-29.3, -6.6) |
| OV6 | -48.4 (-66.9, -29.9) | -5.3 (-16.7, 6.2) |
| OV7 | -32.1 (-48.9, -15.3) | 7.2 (-4.5, 18.9) |
| OV8 | -20.4 (-35.1, -5.7) | 20.3 (9.1, 31.5) |
| OV9 | -6.8 (-18.4, 4.7) | 31.5 (20.3, 42.7) |
| OV10 | 6.3 (-3.9, 16.5) | 44.0 (32.2, 55.7) |
| OV11 | 19.5 (10.3, 28.7) | 58.1 (46.0, 70.1) |
| OV12 | 31.1 (22.2, 39.9) | 73.9 (60.8, 87.1) |
| OV13 | 42.2 (32.9, 51.6) | 89.6 (75.0, 104.2) |
| OV14 | 60.9 (51.0, 70.8) | 107.4 (92.7, 122.2) |
| OV15 | 80.6 (70.6, 90.6) | 132.5 (115.4, 149.6) |
| OV16 | 112.7 (101.0, 124.4) | 187.6 (163.9, 211.3) |

CI, confidence interval; mITT, modified intention-to-treat; OV, ordered value; q6mo, every 6 months active cycle.